Barriers and facilitators to viral hepatitis testing in Uzbekistan: scoping qualitative study among key stakeholders, healthcare workers, and the general population.

Autor: Mazhnaya A; Centre for International Health Protection, Robert Koch Institute, Berlin, Germany. hmazhnaya@gmail.com.; National University of Kyiv-Mohyla Academy, Kyiv, Ukraine. hmazhnaya@gmail.com., Geurts B; Centre for International Health Protection, Robert Koch Institute, Berlin, Germany., Brigida K; Research Institute of Virology, Tashkent, Uzbekistan., Bakieva S; Research Institute of Virology, Tashkent, Uzbekistan., Sadirova S; Research Institute of Virology, Tashkent, Uzbekistan., Witzigmann A; Centre for International Health Protection, Robert Koch Institute, Berlin, Germany., Musabaev E; Research Institute of Virology, Tashkent, Uzbekistan., Brandl M; Department of Infectious Disease Epidemiology, Robert Koch Institute, Berlin, Germany., Weishaar H; Centre for International Health Protection, Robert Koch Institute, Berlin, Germany., Dudareva S; Department of Infectious Disease Epidemiology, Robert Koch Institute, Berlin, Germany., Bcheraoui CE; Centre for International Health Protection, Robert Koch Institute, Berlin, Germany.

Publikováno v: BMC public health [BMC Public Health] 2024 Jun 03; Vol. 24 (1), pp. 1482. Date of Electronic Publication: 2024 Jun 03.

Corilagin alleviates atherosclerosis by inhibiting NLRP3 inflammasome activation via the Olfr2 signaling pathway in vitro and in vivo .

Autor: Mao J; Department of Vascular Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China., Chen Y; Department of Vascular Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China., Zong Q; Department of Vascular Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China., Liu C; Department of Infectious Diseases, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China., Xie J; Department of Infectious Diseases, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China., Wang Y; Department of Vascular Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China., Fisher D; Department of Medical Biosciences, Faculty of Natural Sciences, University of The Western Cape, Cape Town, South Africa., Hien NTT; Hai Phong University of Medicine and Pharmacy, Haiphong, Vietnam., Pronyuk K; Department of Infectious Diseases, O.Bogomolets National Medical University, Kyiv, Ukraine., Musabaev E; Research Institute of Virology, Ministry of Health, Tashkent, Uzbekistan., Li Y; Department of Vascular Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China., Zhao L; Department of Infectious Diseases, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China., Dang Y; Department of Vascular Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.

Publikováno v: Frontiers in immunology [Front Immunol] 2024 May 13; Vol. 15, pp. 1364161. Date of Electronic Publication: 2024 May 13 (Print Publication: 2024).

Assessment of the Impact of the Rotavirus Vaccine Against Severe Rotaviral Diarrhea in Uzbekistan.

Autor: Musabaev E; Research Institute of Virology, Tashkent, Uzbekistan., Ismailov U; Research Institute of Virology, Tashkent, Uzbekistan., Ibadullaeva N; Research Institute of Virology, Tashkent, Uzbekistan. drnargizis@gmail.com., Khikmatullaeva A; Research Institute of Virology, Tashkent, Uzbekistan., Norbaev I; Fund of the State Medical Insurance of Jizzakh Region, Jizzakh, Uzbekistan., Primov U; Bukhara Regional Infectious Diseases Hospital, Bukhara, Uzbekistan., Ahrarova D; 4th City Pediatric Infectious Diseases Hospital, Tashkent, Uzbekistan., Sharapov S; Research Institute of Virology, Tashkent, Uzbekistan., Yusupov U; Bukhara State Medical Institute, Bukhara, Uzbekistan., Latipov R; Research Institute of Virology, Tashkent, Uzbekistan.

Publikováno v: Journal of epidemiology and global health [J Epidemiol Glob Health] 2023 Sep; Vol. 13 (3), pp. 476-484. Date of Electronic Publication: 2023 Jun 10.

Viral hepatitis elimination challenges in low- and middle-income countries-Uzbekistan Hepatitis Elimination Program (UHEP).

Autor: Musabaev E; Research Institute of Virology, Tashkent, Uzbekistan., Estes C; Center for Disease Analysis Foundation, Lafayette, Colorado, USA., Sadirova S; Research Institute of Virology, Tashkent, Uzbekistan.; Center for Disease Analysis Foundation, Lafayette, Colorado, USA., Bakieva S; Research Institute of Virology, Tashkent, Uzbekistan., Brigida K; Research Institute of Virology, Tashkent, Uzbekistan., Dunn R; Research Institute of Virology, Tashkent, Uzbekistan., Kottilil S; University of Maryland School of Medicine, Baltimore, Maryland, USA., Mathur P; University of Maryland School of Medicine, Baltimore, Maryland, USA., Abutaleb A; University of Maryland School of Medicine, Baltimore, Maryland, USA., Razavi-Shearer K; Center for Disease Analysis Foundation, Lafayette, Colorado, USA., Anstiss T; University of Southampton, Southampton, UK., Yusupaliev B; Ministry of Health of the Republic of Uzbekistan, Tashkent, Uzbekistan., Razavi H; Center for Disease Analysis Foundation, Lafayette, Colorado, USA.

Publikováno v: Liver international : official journal of the International Association for the Study of the Liver [Liver Int] 2023 Apr; Vol. 43 (4), pp. 773-784. Date of Electronic Publication: 2023 Jan 18.

Rotavirus disease in Uzbekistan: Cost-effectiveness of a new vaccine

Autor: Isakbaeva, E.T., Musabaev, E., Antil, L., Rheingans, R., Juraev, R., Glass, R.I., Bresee, J.S.

Publikováno v: In Vaccine 2007 25(2):373-380